Masterclass: DTx Reimbursement in the US - PBMs as Coverage Scale Catalysts

Even though demonstrating evidence, building stakeholder advocacy and achieving desired regulatory status are important steps in the DTx commercialization journey, enabling reimbursement pathways at scale is a key adoption condition needed for higher DTx revenue potential. However, most DTx companies struggle to get their products reimbursed. Join this masterclass led by biopharma and DTx reimbursement expert Mike Pace to learn more about  Pharmacy Benefit Managers (PBMs) as an entry point to DTx reimbursement in the US. Mike will walk us through: